| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 73.16% | Morgan Stanley | $13 → $8 | Maintains | Equal-Weight |
| 10/16/2023 | 116.45% | Piper Sandler | $15 → $10 | Maintains | Overweight |
| 07/19/2023 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 05/11/2023 | 181.39% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 05/10/2023 | 159.74% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 03/07/2023 | 224.68% | Piper Sandler | $18 → $15 | Maintains | Overweight |
| 03/02/2023 | 203.03% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 03/02/2023 | 203.03% | Goldman Sachs | $16 → $14 | Maintains | Buy |
| 08/18/2022 | 246.32% | Piper Sandler | $12 → $16 | Maintains | Overweight |
| 08/12/2022 | 224.68% | Morgan Stanley | $11 → $15 | Maintains | Equal-Weight |
| 08/11/2022 | 267.97% | Goldman Sachs | $15 → $17 | Maintains | Buy |
| 07/14/2022 | 224.68% | Goldman Sachs | $12 → $15 | Maintains | Buy |
| 05/16/2022 | 159.74% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 05/13/2022 | 138.1% | Morgan Stanley | $18 → $11 | Maintains | Equal-Weight |
| 05/12/2022 | 159.74% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 04/13/2022 | 203.03% | Goldman Sachs | $28 → $14 | Maintains | Buy |
| 02/15/2022 | 289.61% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
| 08/17/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/17/2021 | 462.77% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 08/17/2021 | 506.06% | Goldman Sachs | → $28 | Initiates Coverage On | → Buy |
| 08/17/2021 | 506.06% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
What is the target price for Cytek Biosciences (CTKB)?
The latest price target for Cytek Biosciences (NASDAQ: CTKB) was reported by Morgan Stanley on October 24, 2023. The analyst firm set a price target for $8.00 expecting CTKB to rise to within 12 months (a possible 73.16% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
The latest analyst rating for Cytek Biosciences (NASDAQ: CTKB) was provided by Morgan Stanley, and Cytek Biosciences maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $13.00 to $8.00. The current price Cytek Biosciences (CTKB) is trading at is $4.62, which is out of the analyst's predicted range.